Jukka Jolkkonen • Piotr Walczak
Editors

2013

Stroke is a major cause of severe disability that poses an enormous healthcare burden. The only effective therapy is thrombolysis when started within 4.5 h of symptoms onset, but, because of the narrow therapeutic time window, only few patients bene fi t from it. Despite extensive research, neuroprotective drugs have all failed in clinical trials. Thus, efforts focused on the pursuit of new cell-based restorative therapies have emerged recently as attractive approaches for the treatment of stroke patients.